Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial.

BACKGROUND & AIMS The incidence of post-TIPS hepatic encephalopathy (HE) could be reduced by using stents with a small diameter. The aim of this study was to compare the incidence of HE and the clinical efficacy of TIPS created with 8- or 10-mm PTFE-covered stents. METHODS Consecutive cirrhotics submitted to TIPS for variceal bleeding or refractory ascites were randomized to receive a 8- or 10-mm covered stent. As recommended by our Ethical Committee, the trial was stopped after the inclusion of 45 patients. RESULTS The two groups were comparable for age, sex, etiology, and psychometric performance. After TIPS, the portosystemic pressure gradient was significantly higher in the 8-mm stent group (8.9+/-2.7 versus 6.5+/-2.7 mmHg; p=0.007). Consequently, the probability of remaining free of complications due to portal hypertension was significantly higher in the 10-mm than in the 8-mm stent group: 82.9% versus 41.9% at one year; log-rank test, p=0.002. In particular, the persistence of ascites with the need for repeated paracentesis was significantly more frequent in the patients treated with 8-mm stent diameter for refractory ascites (log-rank test, p=0.008). The probability of remaining free of HE was similar in both groups. Cumulative survival rate was similar in both groups. CONCLUSIONS The use of 8-mm diameter stents for TIPS leads to a significantly less efficient control of complications of portal hypertension. HE remains an unsolved major problem after TIPS.

[1]  F. Nevens,et al.  Early and long-term clinical and radiological follow-up results of expanded-polytetrafluoroethylene-covered stent-grafts for transjugular intrahepatic portosystemic shunt procedures , 2004, European Radiology.

[2]  P. Kamath,et al.  Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. , 2003, Gastroenterology.

[3]  P. Kamath,et al.  A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts , 2000, Hepatology.

[4]  P. Hayes,et al.  Improved clinical outcome with transjugular intrahepatic portosystemic stent-shunt utilizing polytetrafluoroethylene-covered stents , 2006, European journal of gastroenterology & hepatology.

[5]  C. Ripoll,et al.  Comparison of transjugular intrahepatic portosystemic shunt dysfunction in PTFE-covered stent-grafts versus bare stents. , 2005, European journal of radiology.

[6]  J. Rank,et al.  Development of stenoses in transjugular intrahepatic portosystemic shunts. , 1994, Radiology.

[7]  M. Merli,et al.  Role of determination of partial pressure of ammonia in cirrhotic patients with and without hepatic encephalopathy. , 2003, Journal of hepatology.

[8]  L. Blendis.  Portal Hypertension II , 1996 .

[9]  H. Figulla,et al.  Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Clinical, laboratory, psychometric, and electroencephalographic investigations , 1998, Hepatology.

[10]  R. Franchis,et al.  Portal hypertension II : proceedings of the Second Baveno International Consensus Workshop on Definitions, Methodology, and Therapeutic Strategies , 1996 .

[11]  A. Nicolini,et al.  Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites , 2004, Hepatology.

[12]  H. Rousseau,et al.  Preliminary results of a new expanded-polytetrafluoroethylene-covered stent-graft for transjugular intrahepatic portosystemic shunt procedures. , 2002, AJR. American journal of roentgenology.

[13]  P. Cole,et al.  Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. , 1996, Gastroenterology.

[14]  C. Hildebolt,et al.  Encephalopathy after transjugular intrahepatic portosystemic shunting: analysis of incidence and potential risk factors. , 1997, AJR. American journal of roentgenology.

[15]  J. Roberts,et al.  Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. , 1995, The American journal of gastroenterology.

[16]  Maria Di Giovanni,et al.  Reliability of endoscopy in the assessment of variceal features: The Italian Liver Cirrhosis Project , 1987 .

[17]  Daniela Mapelli,et al.  Variability of Trail Making Test, Symbol Digit Test and Line Trait Test in normal people. A normative study taking into account age-dependent decline and sociobiological variables , 2002, Aging clinical and experimental research.

[18]  F. Wong,et al.  Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. , 2007, Gastroenterology.

[19]  E. Ring,et al.  Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients. , 1995, Gastroenterology.

[20]  A. Burroughs,et al.  TIPS for refractory ascites: a single-centre experience , 2009, Journal of Gastroenterology.

[21]  C. Pinson,et al.  Incidence of shunt occlusion or stenosis following transjugular intrahepatic portosystemic shunt placement. , 1994, Gastroenterology.

[22]  M. Maynar,et al.  Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. , 1996, Gastroenterology.

[23]  M. Merli,et al.  Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. , 2005, Journal of hepatology.

[24]  J. Rodés,et al.  Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. , 1998, Gastroenterology.

[25]  K. Reddy,et al.  The North American Study for the Treatment of Refractory Ascites. , 2003, Gastroenterology.

[26]  A. Freedman,et al.  Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: Results of a prospective controlled study , 1994, Hepatology.

[27]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.

[28]  H. Rousseau,et al.  Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. , 2004, Gastroenterology.

[29]  P. Rossi,et al.  Use of a laryngeal mask in transjugular intrahepatic portosystemic shunt procedures. , 1998, Journal of vascular and interventional radiology : JVIR.

[30]  M. Merli,et al.  Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: A randomized multicenter trial , 1998 .

[31]  Alessio Farcomeni,et al.  Incidence, Natural History, and Risk Factors of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt With Polytetrafluoroethylene-Covered Stent Grafts , 2008, The American Journal of Gastroenterology.

[32]  Eter,et al.  A COMPARISON OF PARACENTESIS AND TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNTING IN PATIENTS WITH ASCITES , 2000 .

[33]  M. Merli,et al.  Polytetrafluoroethylene-Covered Stent Grafts for TIPS Procedure: 1-Year Patency and Clinical Results , 2004, American Journal of Gastroenterology.

[34]  I. J. Sarfeh,et al.  Partial Versus Total Portacaval Shunt in Alcoholic Cirrhosis Results of a Prospective, Randomized Clinical Trial , 1994, Annals of surgery.

[35]  R. Edwards,et al.  Results of a retrospective multicenter trial of the Viatorr expanded polytetrafluoroethylene-covered stent-graft for transjugular intrahepatic portosystemic shunt creation. , 2004, Journal of vascular and interventional radiology : JVIR.

[36]  T. Kroencke,et al.  Covered transjugular intrahepatic portosystemic stents maintain lower portal pressure and require fewer reinterventions than uncovered stents , 2004, Scandinavian journal of gastroenterology.

[37]  L. Seeff,et al.  Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. , 1977, Gastroenterology.

[38]  H. Conn.  Partial versus total portacaval shunt in alcoholic cirrhosis. Results of a prospective, randomized clinical trial: Sarfeh J, Rypins EB. Ann Surg 1994; 219:353–361 , 1995 .

[39]  G. Passalacqua,et al.  TIPS with expanded polytetrafluoroethylene-covered stent: results of an Italian multicenter study. , 2005, AJR. American journal of roentgenology.

[40]  P. Hayes,et al.  Analysis of prognostic variables in the prediction of mortality, shunt failure, variceal rebleeding and encephalopathy following the transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage. , 1995, Journal of hepatology.

[41]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[42]  Franz Hackl,et al.  Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE‐covered stentgrafts versus bare stents , 2003, Hepatology.

[43]  M. Hudson,et al.  Patency and reintervention rates during routine TIPSS surveillance , 1998, CardioVascular and Interventional Radiology.

[44]  O. Riggio,et al.  Polytetrafluoroethylene-covered nitinol stent-graft for transjugular intrahepatic portosystemic shunt creation: 3-year experience. , 2004, Radiology.

[45]  J. Lammer,et al.  Creation of transjugular intrahepatic portosystemic shunts with stent-grafts: initial experiences with a polytetrafluoroethylene-covered nitinol endoprosthesis. , 2001, Radiology.

[46]  V. Vilgrain,et al.  Transjugular intrahepatic portosystemic shunts: Comparison with paracentesis in patients with cirrhosis and refractory ascites: A randomized trial , 1996 .

[47]  H. Blum,et al.  Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding , 1997, The Lancet.